Research programme: engineered T cell immunotherapies - Fate Therapeutics/Memorial Sloan Kettering Cancer Center

Drug Profile

Research programme: engineered T cell immunotherapies - Fate Therapeutics/Memorial Sloan Kettering Cancer Center

Latest Information Update: 06 Oct 2016

Price : $50

At a glance

  • Originator Fate Therapeutics; Memorial Sloan-Kettering Cancer Center
  • Class T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Sep 2016 Fate Therapeutics and Memorial Sloan Kettering Cancer Center agree to co-develop engineered T cell immunotherapies in USA
  • 07 Sep 2016 Fate Therapeutics and Memorial Sloan Kettering Cancer Center has patent protection for engineered T cell immunotherapies
  • 07 Sep 2016 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top